Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4459771 | 0.84 | GRM2 (0.40) | GRM2BACE1MMP2MMP3MMP9 | |
| SCHEMBL4460629 | 0.81 | GRM2 (0.40) | GRM2MMP2MMP3MMP9 | |
| SCHEMBL4445297 | 0.81 | GRM2 (0.38) | GRM2MMP2MMP3MMP9 | |
| SCHEMBL4463016 | 0.78 | ALDH1A1 (0.36) | GRM2BACE1 | |
| SCHEMBL4453549 | 0.70 | SMN1; SMN2 (0.39) | GRM2MMP2MMP3MMP9 | |
| SCHEMBL4452501 | 0.63 | FAAH (0.35) | GRM2BACE1MMP2MMP3MMP9 | |
| SCHEMBL4450103 | 0.61 | GAA (0.40) | GRM2BACE1MMP2MMP3MMP9 | |
| SCHEMBL4458256 | 0.59 | IDH1 (0.39) | MMP2MMP3MMP9 | |
| SCHEMBL4454486 | 0.58 | GAA (0.35) | GRM2BACE1MMP2MMP3MMP9 | |
| SCHEMBL4480093 | 0.58 | ELANE (0.38) | GRM2MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | CYP2D6, ABCG2, CYP2B6 | GRM2 4432/4885CTSD 2068/4885BACE1 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.